PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that it is investigating Seres Therapeutics, Inc. (NASDAQ: MCRB) (“Seres”) on behalf of the company’s investors.
Since June 2023, shares of Seres’ common stock have declined in value from a trading price of over $5.00 per share to a current trading price of less than $1.00 per share, a cumulative decline of 80% in value.
The investigation seeks to determine whether the company’s officers and/or directors breached their fiduciary duties or violated the securities laws in connection with recent corporate actions.
Seres stockholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email (email@example.com / firstname.lastname@example.org) or online at https://kaskelalaw.com/cases/seres-therapeutics/ , for additional information about this investigation and their legal rights and options.
Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
This notice may constitute attorney advertising in certain jurisdictions.
- Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) - December 9, 2023
- FSR INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Fisker Inc. Investors with Substantial Losses Have Opportunity to Lead Case - December 9, 2023